SEC Form 4 · accession 0000899243-18-018143

Eidos Therapeutics, Inc. · EIDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jun 22, 2018

Accepted (ET)

Jun 26, 2018 · 4:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001731831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 22, 2018	C	18,826,417	$0.00	A	18,826,417	D
Common Stock	Jun 22, 2018	F	211,762	$17.00	D	18,614,655	D
Common Stock	Jun 22, 2018	P	1,000,000	$17.00	A	19,614,655	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrants^F1	$10.8348	Jun 22, 2018	X	332,262	D	—	—	Series B Preferred Stock	332,262	0	D
Series B Preferred Stock^F2	—	Jun 22, 2018	X	332,262	A	—	—	Common Stock	397,385	2,909,029	D
Series B Preferred Stock^F2	—	Jun 22, 2018	C	2,909,029	D	—	—	Common Stock	3,479,198	0	D
Series Seed Preferred Stock^F2	—	Jun 22, 2018	C	12,832,123	D	—	—	Common Stock	15,347,219	0	D

F1Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
F2Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.